Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)
China · Delayed Price · Currency is CNY 4.870
+0.070 (1.46%)
Oct 23, 2026, 3:00 PM CST
SHA:603567 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,570 | 8,388 | 10,897 | 11,423 | 11,988 | 14,412 | |
Market Cap Growth | -58.48% | -23.03% | -4.61% | -4.71% | -16.82% | 52.08% |
Enterprise Value | 7,685 | 11,472 | 13,767 | 13,636 | 13,478 | 17,271 |
Last Close Price | 4.87 | 8.93 | 11.46 | 11.80 | 12.35 | 14.68 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 24.87 | 24.16 | 64.65 | 43.40 |
Forward PE | - | 18.18 | 18.18 | 18.18 | 18.18 | 22.34 |
PS Ratio | 12.05 | 10.52 | 4.03 | 3.64 | 2.85 | 3.49 |
PB Ratio | 0.76 | 1.34 | 1.31 | 1.42 | 1.69 | 2.04 |
P/TBV Ratio | 0.93 | 1.61 | 1.60 | 1.69 | 1.90 | 2.12 |
P/FCF Ratio | 10.28 | 33.08 | - | - | - | - |
P/OCF Ratio | 9.38 | 26.04 | 66.32 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 20.26 | 14.39 | 5.09 | 4.35 | 3.20 | 4.18 |
EV/EBITDA Ratio | - | - | 18.55 | 37.43 | - | 42.55 |
EV/EBIT Ratio | - | - | 22.83 | 73.50 | - | 63.88 |
EV/FCF Ratio | 17.29 | 45.24 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.52 | 0.50 | 0.40 | 0.39 | 0.41 | 0.42 |
Debt / EBITDA Ratio | - | - | 4.41 | 8.38 | - | 7.23 |
Debt / FCF Ratio | 7.07 | 12.30 | - | - | - | - |
Net Debt / Equity Ratio | 0.51 | 0.48 | 0.27 | 0.21 | 0.26 | 0.20 |
Net Debt / EBITDA Ratio | -2.56 | -3.17 | 3.00 | 4.62 | -31.21 | 3.40 |
Net Debt / FCF Ratio | 6.92 | 11.97 | -89.56 | -2.93 | -2.55 | -1.56 |
Asset Turnover | 0.03 | 0.07 | 0.22 | 0.26 | 0.36 | 0.38 |
Inventory Turnover | 0.69 | 0.85 | 1.21 | 2.14 | 4.07 | 3.34 |
Quick Ratio | 0.83 | 0.81 | 2.11 | 2.16 | 1.27 | 2.04 |
Current Ratio | 1.32 | 1.26 | 2.85 | 2.60 | 1.65 | 2.37 |
Return on Equity (ROE) | -22.65% | -18.80% | 5.34% | 6.17% | 2.70% | 5.30% |
Return on Assets (ROA) | -7.57% | -6.01% | 2.99% | 0.96% | -1.17% | 1.55% |
Return on Invested Capital (ROIC) | -14.90% | -11.33% | 4.97% | 1.94% | -1.59% | 2.54% |
Return on Capital Employed (ROCE) | -20.70% | -17.20% | 5.90% | 1.90% | -2.80% | 3.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -34.07% | -16.29% | 4.02% | 4.14% | 1.55% | 2.30% |
FCF Yield | 9.73% | 3.02% | -0.23% | -5.02% | -6.10% | -6.12% |
Dividend Yield | - | - | 1.29% | 1.65% | 0.22% | 0.69% |
Payout Ratio | - | - | 74.00% | 33.48% | 131.34% | 43.28% |
Buyback Yield / Dilution | 0.04% | 0.01% | 0.01% | 0.14% | -8.87% | -1.82% |
Total Shareholder Return | 0.04% | 0.01% | 1.30% | 1.78% | -8.65% | -1.13% |